Cardiovascular and renal outcomes of Semaglutide in patients with Type 2 Diabetes Mellitus with established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease: A Meta-Analysis
Type 2 diabetes mellitus (T2DM), atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD) constitute a high risk triad for major adverse cardiovascular and renal events. Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP 1-RA), has emerged as an important therapeutic option....